These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20516123)

  • 41. Oncogenic ras fails to restore an in vivo tumorigenic phenotype in embryonic stem cells lacking vascular endothelial growth factor (VEGF).
    Shi YP; Ferrara N
    Biochem Biophys Res Commun; 1999 Jan; 254(2):480-3. PubMed ID: 9918864
    [TBL] [Abstract][Full Text] [Related]  

  • 42. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
    Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
    Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
    Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
    FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of a conditional liver tumor model by mifepristone-inducible Cre recombination to control oncogenic kras V12 expression in transgenic zebrafish.
    Nguyen AT; Koh V; Spitsbergen JM; Gong Z
    Sci Rep; 2016 Jan; 6():19559. PubMed ID: 26790949
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A model for RAS mutation patterns in cancers: finding the sweet spot.
    Li S; Balmain A; Counter CM
    Nat Rev Cancer; 2018 Dec; 18(12):767-777. PubMed ID: 30420765
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hyperpigmentation and melanocytic hyperplasia in transgenic mice expressing the human T24 Ha-ras gene regulated by a mouse tyrosinase promoter.
    Powell MB; Hyman P; Bell OD; Balmain A; Brown K; Alberts D; Bowden GT
    Mol Carcinog; 1995 Feb; 12(2):82-90. PubMed ID: 7662120
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS
    Kun EHS; Tsang YTM; Lin S; Pan S; Medapalli T; Malpica A; Richards JS; Gershenson DM; Wong KK
    Sci Rep; 2020 Nov; 10(1):20678. PubMed ID: 33244099
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Downregulation of Notch Signaling in Kras-Induced Gastric Metaplasia.
    Chung WC; Zhou Y; Atfi A; Xu K
    Neoplasia; 2019 Aug; 21(8):810-821. PubMed ID: 31276933
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer.
    Roh JI; Lee J; Sung YH; Oh J; Hyeon DY; Kim Y; Lee S; Devkota S; Kim HJ; Park B; Nam T; Song Y; Kim Y; Hwang D; Lee HW
    Oncogene; 2020 Sep; 39(36):5876-5887. PubMed ID: 32728173
    [TBL] [Abstract][Full Text] [Related]  

  • 50. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma.
    Doyle B; Morton JP; Delaney DW; Ridgway RA; Wilkins JA; Sansom OJ
    J Pathol; 2010 Oct; 222(2):129-37. PubMed ID: 20662002
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An ultra-sensitive method to detect mutations in human
    Li S; Counter CM
    Small GTPases; 2022 Jan; 13(1):287-295. PubMed ID: 35658790
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
    Green S; Trejo CL; McMahon M
    Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Methods to generate genetically engineered mouse models of soft tissue sarcoma.
    Dodd RD; Añó L; Blum JM; Li Z; Van Mater D; Kirsch DG
    Methods Mol Biol; 2015; 1267():283-95. PubMed ID: 25636474
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
    Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
    Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activation Of Wild-Type Hras Suppresses The Earliest Stages Of Pancreatic Cancer.
    Weyandt J
    Redox Biol; 2015 Aug; 5():414. PubMed ID: 28162272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ras-induced melanoma transformation is associated with the proteasomal degradation of the transcriptional repressor ICER.
    Healey M; Crow MS; Molina CA
    Mol Carcinog; 2013 Sep; 52(9):692-704. PubMed ID: 22488648
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of cellular protooncogene activation and transformation-related activity of human melanocytes and metastatic melanoma.
    Husain Z; FitzGerald GB; Wick MM
    J Invest Dermatol; 1990 Nov; 95(5):571-5. PubMed ID: 2121834
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Induction of melanoma in murine macrophage inflammatory protein 2 transgenic mice heterozygous for inhibitor of kinase/alternate reading frame.
    Yang J; Luan J; Yu Y; Li C; DePinho RA; Chin L; Richmond A
    Cancer Res; 2001 Nov; 61(22):8150-7. PubMed ID: 11719444
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background.
    Ackermann J; Frutschi M; Kaloulis K; McKee T; Trumpp A; Beermann F
    Cancer Res; 2005 May; 65(10):4005-11. PubMed ID: 15899789
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth.
    Barceló C; Paco N; Morell M; Alvarez-Moya B; Bota-Rabassedas N; Jaumot M; Vilardell F; Capella G; Agell N
    Cancer Res; 2014 Feb; 74(4):1190-9. PubMed ID: 24371225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.